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1. Introduction 
Renal cell carcinoma accounts for 80% of all kidney cancers -worldwide; the tumor staging 
at diagnosis ranges from small, low-stage tumors to more advanced neoplasms [1-5]. The  
survival rate has increased in recent years: nowadays,  patients with localized disease have a 
5-year survival >80% but in those with distant metastatic RCC, 5-year survival is <10% [6-8]. 
The increase in overall survival was due, at least in part, to improved surgical techniques 
[9,10]. Until recently cytokines (interleukin-2 or interferon-alpha), were the mainstay of 
systemic treatment despite low response rates and significant toxicity [11,12]. 
Since 2005, six targeted therapies for advanced/metastatic RCC were approved by both the 
FDA and EMA:  three are multitargeted tyrosine kinase inhibitors (TKIs), sorafenib (SO), 
sunitinib (SU) and pazopanib (PZ), two are oral mTOR inhibitors, temsirolimus (TS) and 
everolimus (EV) and one is the anti-VEGF monoclonal antibody bevacizumab (BV),  
administered in combination with IFN-alpha [13]. These new agents improved  the 
progression free survival (PFS) and the overall survival (OS) in several subgroups of 
patients; however, expert opinion on the optimal therapeutic strategy is divided.  
Two main therapeutic approaches—use of these new agents in combination or 
sequentially—have been studied to increase efficacy and tolerability. Sequential therapy is 
the current standard of care in the treatment of advanced RCC as existing combination 
regimens have a high incidence of adverse events without a substantial increase in efficacy. 
The use of sequential therapy provides a number of important advantages: patients who are 
refractory to one or more targeted agent(s) may benefit from treatment with a different 
agent; there is no/limited cross-resistance between agents and patients experiencing disease 
progression with one anti-angiogenic agent can subsequently benefit from treatment with 
another  [14,15].  
The results of recent phase III randomized controlled trials (RCTs) prompted the National 
Comprehensive Cancer Network (NCCN) and the European Association of Urology (EAU) 
to update their clinical practice guidelines for the treatment of metastatic RCC [16,17]. The 
EAU recommended SU as a first-line therapy in low- and intermediate-risk patients and 
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concluded that SO is effective as second-line treatment after failure of cytokine therapy or in 
patients unfit for cytokines [18]. Clinical evidence supports the efficacy of sequential 
treatment with SU/SO [19]; however, the optimal sequence for SO and SU is still under 
debate, and additional evidence on the optimal use of sequential targeted therapies is 
advocated.  
In this retrospective study – the preliminary results of which have been previously 
presented [20] - the safety and efficacy of different sequential schemes of targeted therapies, 
in patients with advanced/metastatic RCC were studied. 
2. Methods 
2.1 Patients  
This retrospective study was conducted at the ‘Istituto Nazionale Tumori  of Milan’ 
(National Institute of Tumors, Milan, Italy) – one of the most important Italian institutions 
for cancer diagnosis and treatment - between  January 2004 and  July 2010. Patients were 
patients aged ≥18 years with advanced/metastatic RCC and a life expectancy of >3 months 
who had been treated with antiangiogenic  therapy (one or more) were eligible for 
enrollment in this retrospective study. Patients with Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0, 1 or 2 were included. A number of patients enrolled in 
this study had previously taken part in a range of prospective trials including TARGET , the 
EU-ARCCS , RECORD-1 , AXIS , AVOREN  and ROSORC  at our centre.  
3. Treatment 
Patients received a range of different systemic agents – SO, SU, BV, EV, TS and axitinib (AX) 
alone or in combination, and could have received a previous treatment with cytokines. SO 
was administered orally at a dose of 400 mg twice daily and SU at a daily dose of 50 mg 
orally with a 4 weeks on 2 weeks off schedule. BV was administered iv at 10 mg/Kg every 2 
weeks in combination with Interferon-a subcutaneously, EV was administered orally at 10 
mg daily continuously, TS iv weekly at 25 mg/dose and AX at 10 mg/daily orally 
continuously. Patients received systemic therapy until disease progression or the presence 
of serious adverse events.  
4. Study assessments 
Study assessments were conducted at baseline and once a month thereafter. Baseline 
characteristics were taken ≤28 days after the start of treatment. Drug safety and tolerability 
were assessed using the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCTCA version 3). Efficacy was assessed by progression-free survival 
(PFS) and overall survival (OS) according to the Motzer  classification  [21]. PFS was defined 
as the time from start of systemic treatment to death or disease progression whichever 
occurred first. Disease progression was evaluated using the Response Evaluation criteria in 
Solid Tumours (RECIST, version 1.0) by the treating physician. Assessments were 
performed monthly (every 3 weeks for patients on sunitinib, due to the schedule of 
administration for this drug). Patients with Bellini duct RCC were excluded from the 
efficacy analysis, due to the different histology of the tumor. 
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5. Statistical analyses  
All clinical and instrumental variables and toxicity data were analyzed by descriptive 
statistics: mean, standard deviation, minimum, and maximum values for continuous 
variables, and absolute and relative frequencies for categorical variables. Curves relevant to 
OS (overall, Motzer and according to therapy option) were estimated by the Kaplan–Meier 
method and compared by means of the log-rank test. Reports of AEs were categorized 
according to type, severity, and outcome. A p value <0.05 was considered statistically 
significant.  
6. Results  
A total of 310 patients with metastatic RCC were observed, and followed-up for a median of 
37 months (range 21–49 months). Patient characteristics at baseline are shown in Table 1.  
 
Patients included in database 310
Median age (years) 
Range 
62  
55–69
Male 
Female 
229  (74%) 
81
ECOG PS 
0 
1 
2 
 
168  (54%) 
123  (40%) 
19  (6%)
Histology 
Clear-cell   
Papillary 
Bellini 
Chromophobe 
Oncocytoma 
UNK   
  
268  (86.4%) 
27 (8.7%) 
7  (2.2%) 
6 (1.9%) 
1 (0.3%) 
1  (0.3%)
Previous nephrectomy, % 273   (88.1%)
Fuhrman grade, % 
1 
2 
3 
4 
Missing 
 
15  (5.58%) 
93 (34.57%) 
118 (43.87%) 
43  (15.99%) 
41
Motzer criteria  
High 
Low 
Intermediate 
 
64 (20.6%) 
100 (32.3%) 
146   (47.10%)
Targeted therapies % 
1 
2 
3 
4 
 
163   (52.6%) 
113  (36.5%) 
30  (9.7%) 
4  (1.29%)
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Number of disease sites 
1 
2 
3 
4 
5 
 
121  (39.0%) 
107  (34.5%) 
67  (21.2%) 
12  (3.9%) 
3  (0.9%)
Sites of disease (n=599) 
Bone 
Brain 
Liver 
Lung 
Lymph nodes 
Pancreas 
Thyroid  
Other 
 
88  (28.39%) 
16  (5.16%) 
59  (19.03%) 
204  (65.81%) 
119  (38.39%) 
15  (4.84%) 
4 (1.29%) 
94  (30.32%)
Table 1. Patient characteristics at baseline 
Overall the majority of patients (163; 53.9%) received one treatment line with systemic 
agents while 113 (36.5%) received two, 30 (9.7%) received three line and four patients (1.3%) 
received four. One-sided analysis of variance showed that the Motzer classification/score 
was predictive regarding the number of therapy lines (Fisher 8.49, p<0.01) with the mean 
number of treatments significantly lower in the high-risk group (p<0.05) than in the 
low/intermediate risk groups (t-tests). Overall the majority of patients 196/310 received  SO 
as first line followed by SU in 96 cases or SU, in 63 cases followed by SO in 13 cases). The 
remaining 51/310 received other systemic agents in sequence (BV, TS, AX alone or in 
sequence/combination with SO and SU).  
Median OS was 22 months and the 5-year OS was 23.4% (95% CI 16.7, 30.0%) (Figure 1).  
 
Fig. 1. Overall survival  
303  251   185   136   100    73     50      32     17     17      17    17    
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The Motzer criteria were validated as prognostic factors in both the uni- and multi-variate 
analysis (p<0.001). The median and 5-year OS was 43 months and 42.8% in low-risk patients, 
21 months and 15.9% in intermediate risk patients and 8 months in patients with poor risk 
(Figure 2).  
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Fig. 2. Overall survival according to Motzer classification 
Interestingly in both the multi- and uni-variate analysis there were no significant differences 
in the hazard ratios when SO+SU are compared with SU+SO and with other therapies 
(Table 2, 3 and Figure 3).  
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Fig. 3. Overall survival with sorafenib and sunitinib compared with other therapies 
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In detail, the PFS was 17 months with the specific sequence of SO+SU (9 months + 8 months) 
and 16 months with SU+SO (12 months + 4 months). The median PFS of first line treatment 
with either SO or SU was 10.5 months. 
Furthermore in the multivariate overall survival analysis un-adjusted for the Motzer 
classification (Table 3) the risk was nearly 1.5 times higher in those patients who had 
previously been treated with cytokines compared with those who had not received 
cytokines (p<0.033). 
 Hazard ratio (95% CI) p 
Age   
10 years increasing 0.98 (0.86; 1.11) 0.735 
Sex   
Male vs. female 1.09 (0.77; 1.55) 0.635 
ECOG PS    
1 vs. 0 1.69 (1.25; 2.29) 
<0.001 
2 vs. 0 2.62 (1.39; 4.95) 
Cytokine   
Yes vs. no 1.28 (0.95 ; 1.72) 0.101 
Histology   
Papillary vs. clear cell 1.39 (0.85; 2.27) 
0.247 
Non clear cell vs. Clear cell 1.47 (0.75; 2.89) 
Nephrectomy   
Yes vs. no 0.41 (0.26; 0.65) <0.001 
Motzer criteria   
Intermediate vs. low risk 2.30 (1.57; 3.35) 
<0.001 
High vs. low risk 7.90 (5.07;12.31) 
Therapeutic choice   
Other option vs. Sorafenib+sunitinib 0.77 (0.51;1.17) 
0.212 
Sunitinib+sorafenib vs. sorafenib+sunitinib 0.69 (0.41;1.16) 
ECOG PS = Eastern Cooperative Group Performance Score 
Table 2. Univariable overall survival analysis 
7. Adverse events 
The most commonly reported treatment-related all grade adverse events (AEs) were typical 
of those reported with TKIs including asthenia, hand-foot syndrome, hypertension, 
diarrhea, mucositis,  hypothyroidism and most of these were mild or moderate in intensity 
(Grade 1 or 2).  Overall, 61 (19.68%) patients experienced AEs Grade ≥3 (Table 4) and there 
were a total of 65 Grade ≥3 AEs, and three patients experienced a Grade 4 event (two 
patients receiving SU+SO had cardiac failure and one receiving SO+SU had a cardiac 
stroke). The percentage of patients experiencing adverse events Grade ≥3 was similar in 
patients treated when SO was given as in those treated first with SU then SO (18.88 and 
17.46%). In those treated with other systemic therapies there was a tendency to a higher 
incidence of AEs (25.5%). Furthermore the nature and severity of AEs groups did not differ 
if SO or SU was given first.  
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 Adjusted for Motzer 
criteria 
Not adjusted for Motzer criteria  
 Hazard ratio 
(95% CI) 
p Hazard ratio 
(95% CI) 
p 
Age     
10 years increasing 0.98 (0.85; 1.12) 0.767 0.91 (0.80; 1.04) 0.180 
Sex     
Males vs. females 0.91 (0.62; 1.32) 0.611 1.09 (0.76; 1.59) 0.631 
ECOG PS     
1 vs. 0 1.09 (0.78; 1.54) 
0.838 
1.53 (1.11; 2.12) 
0.003 
2 vs. 0 0.95 (0.48; 1.89) 2.42 (1.27; 4.59) 
Cytokine      
Yes vs. no 1.26 (0.91; 1.75) 0.169 1.41 (1.03; 1.94) 0.033 
Histology     
Papillary vs. clear cell 1.35 (0.81; 2.24) 
0.478 
1.42 (0.86; 2.35) 
0.285 
Non clear cell vs. clear cell 1.19 (0.60; 2.39) 1.38 (0.69; 2.74) 
Nephrectomy     
Yes vs. no 0.59 (0.35; 0.98) 0.041 0.40 (0.24; 0.67) 0.001 
Motzer criteria     
Intermediate vs. low risk 2.15 (1.44; 3.21) 
<0.001 
- 
- High vs. low risk 7.23 (4.42; 
11.83) 
- 
Therapeutic choice     
Other options vs. 
sorafenib+sunitinib 
0.84 (0.55; 1.29) 
0.388 
0.85 (0.56; 1.30) 
0.675 
Sunitinib+sorafenib vs. 
Sorafenib+sunitinib 
0.70 (0.40; 1.23) 0.85 (0.49; 1.47) 
ECOG PS = Eastern Cooperative Group Performance Score 
Table 3. Multivariable overall survival analysis 
 
Adverse event    N  % (N/310)
Asthenia                     36  11.61
Hand-foot syndrome            13   4.19
Anemia                       4   1.29
Cardiac failure             2   0.65
Hypertension                 2   0.65
Mucositis                    2   0.65
Abdominal pain                 1   0.32
Cardiac stroke                1   0.32
Fever                       1   0.32
Macroematuria                1   0.32
Nausea                       1   0.32
Rash                         1   0.32
Table 4. Adverse events Grade ≥3 (patients may have experienced one or more events)  
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8. Discussion  
Despite improvements in therapy, RCC eventually progresses during therapy and other 
agent(s) need to be administered in an attempt to control the disease.  
This large-scale retrospective analysis was carried out to investigate the effects of systemic 
therapy in general and in particular to compare the efficacy and safety of different 
sequential approaches with targeted therapies in controlling the disease progression of 
patients with RCC. Importantly, our results show that treatment with TKIs improves 
survival. In fact the median OS for patients with advanced RCC has increased from around 
13 months before the introduction of TKIs to around 22 months in the last decade and the 
median OS of 22 months observed in the present study provides further evidence to support 
the importance of use of TKI in patients with advanced RCC. In addition, to our knowledge 
most studies have considered PFS, and not OS, as the major determinant of clinical efficacy 
of any sequential therapy for the treatment of RCC: our study provides new evidence on OS 
even in a large unselected population from a single institution. Of note, a relevant 
proportion of patients received sorafenib as a first-line agent, despite current 
recommendations suggest this molecule as a second-line treatment, and sunitinib at 
progression of disease. This therapeutic strategy did not result in any worsening of clinical 
outcomes and in a similar tolerability with respect to the other therapeutic strategies 
assessed. Even if this study was not designed to evaluate the feasibility of sorafenib as a 
first-line agent, and therefore we are unable to draw any conclusion, we believe that this 
finding could be of some interest in the current therapeutic scenario of RCC patients. 
In addition, the Motzer criteria resulted significant prognostic factors in both the uni- and 
multi-variate analysis. On this basis, we suggest that these criteria should – at present - be 
regarded to as the most useful tool for the definition of prognosis and, as a consequence, for 
the optimization of therapy for every single patient. 
Of note, the findings reported in the present report were obtained in a real-life scenario, on a 
large population of unselected patients: it has been suggested that observational trials can 
expand upon outcomes of randomized controlled trials, which are necessarily conducted in 
highly-selected patients [22]. 
In most patients with advanced RCC the objective of treatment is to stabilize disease and 
prolong survival and there is good evidence that this can be achieved with sequencing 
systemic agents. The use of this therapeutic approach, in fact, may determine a relevant 
benefit in terms of OS and quality of life, independently from the specific sequence of 
targeted therapies used. 
Our study confirms the suitability of a TKI sequential therapy. This finding is in line with 
recent evidence, albeit collected in retrospective studies, which seems to support that the use 
of SO before SU, rather than vice versa may be more effective in extending PFS (Table 5). In 
addition, some studies suggest that SO may be associated with a more favorable safety profile 
than more potent SU, in terms of incidence of changes in blood counts and anemia [23,24]. 
The major limitations of the current study was that the sample size was not randomized and 
the data were collected retrospectively. In addition the study populations were very 
hoeterogenous with much patients received the sequence TKI followed TKI and only few 
cases treated with bevacizumab, everolimus, temsirolimus and axitinib.  
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Source  n 1st PFS (months) 2nd PFS (months) 
Sorafenib→Sunitinib
Eichelberg et al. 30 8.7 10.3 
Dudek et al.  29 5.1 18.0 
Porta et al.  83 9.8 8.4 
Procopio et al.  50 9.5 8.3 
Sablin et al.   68 6.0 6.5 
Zimmerman et al. 22 11.5 5.0 
Sunitinib→Sorafenib
Dudek et al.  20 5.8 8.5 
Porta et al.  87 8.3 3.7 
Sablin et al.  22 5.1 3.9 
VEGFi→Sorafenib
Garcia et al  48 8.7 3.7 
PFS = progression-free survival; TTP = time to progression. 
Table 5. Summary of sorafenib and sunitinib sequence data (reproduced from ref 24) 
In conclusion, despite the major breakthrough introduced by targeted therapies, further 
research is necessary to shed new lights on the most effective use of these drugs in clinical 
practice: in particular, the optimal sequence of TKIs has yet to be established.  
Our study supports – however -  the importance of TKI treatment in RCC patients to 
improve OS. In addition, it suggests that factors other than the specific sequence of 
treatment, like the Motzer classification, influence the OS in a large unselected population 
from clinical practice collected in a single institution. On the basis of these results and of 
current evidence reported in literature is now clear that there is not one therapy that will 
benefit all patients and treatment should be tailored to meet individual circumstances and 
needs. Physicians should therefore base their treatment decisions not only on data from 
RCTs but also on clinical experience and judgment  
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